Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.28 USD | -0.84% | -1.33% | -16.88% |
Financials (USD)
Sales 2024 * | 1.76M | Sales 2025 * | 8.84M | Capitalization | 2.89B |
---|---|---|---|---|---|
Net income 2024 * | -221M | Net income 2025 * | -262M | EV / Sales 2024 * | 1,226 x |
Net cash position 2024 * | 727M | Net cash position 2025 * | 650M | EV / Sales 2025 * | 253 x |
P/E ratio 2024 * |
-13.1
x | P/E ratio 2025 * |
-11.8
x | Employees | 255 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Latest transcript on Xenon Pharmaceuticals Inc.
1 day | -0.84% | ||
1 week | -1.33% | ||
Current month | -5.82% | ||
1 month | -10.40% | ||
3 months | -18.89% | ||
6 months | +13.44% | ||
Current year | -16.88% |
Managers | Title | Age | Since |
---|---|---|---|
Ian Mortimer
CEO | Chief Executive Officer | 48 | 13-10-20 |
Simon Pimstone
FOU | Founder | 56 | 96-11-04 |
Sherry Aulin
DFI | Director of Finance/CFO | 41 | 10-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Clarence Machado
BRD | Director/Board Member | 60 | 20-11-04 |
Mohammad Azab
BRD | Director/Board Member | 68 | 03-09-30 |
Justin Gover
BRD | Director/Board Member | 53 | 23-08-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 14 M€ | -6.04% | ||
0.22% | 0 M€ | 0.00% | - | |
0.22% | 0 M€ | 0.00% | - | |
0.20% | 12 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 38.29 | -0.83% | 264,337 |
24-05-28 | 38.61 | +0.63% | 331,221 |
24-05-24 | 38.37 | -0.23% | 193,372 |
24-05-23 | 38.46 | -0.88% | 591,856 |
24-05-22 | 38.8 | -0.46% | 418,657 |
Delayed Quote Nasdaq, May 29, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.88% | 2.89B | |
+8.38% | 114B | |
+10.13% | 104B | |
-11.69% | 22.5B | |
+1.69% | 22.57B | |
-11.18% | 17.95B | |
-41.90% | 16.48B | |
-16.00% | 15.82B | |
+2.28% | 13.55B | |
+20.54% | 10.99B |
- Stock Market
- Equities
- XENE Stock